tiprankstipranks
Trending News
More News >
Altamira Therapeutics Ltd. (CYTOF)
:CYTOF
US Market

Altamira Therapeutics (CYTOF) Price & Analysis

Compare
599 Followers

CYTOF Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.06%<0.01%100.00%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

CYTOF FAQ

What was Altamira Therapeutics Ltd.’s price range in the past 12 months?
Altamira Therapeutics Ltd. lowest stock price was $0.05 and its highest was $1.53 in the past 12 months.
    What is Altamira Therapeutics Ltd.’s market cap?
    Altamira Therapeutics Ltd.’s market cap is $354.36K.
      When is Altamira Therapeutics Ltd.’s upcoming earnings report date?
      Altamira Therapeutics Ltd.’s upcoming earnings report date is Sep 03, 2025 which is in 54 days.
        How were Altamira Therapeutics Ltd.’s earnings last quarter?
        Altamira Therapeutics Ltd. released its earnings results on Apr 30, 2025. The company reported -$0.883 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$0.273.
          Is Altamira Therapeutics Ltd. overvalued?
          According to Wall Street analysts Altamira Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Altamira Therapeutics Ltd. pay dividends?
            Altamira Therapeutics Ltd. does not currently pay dividends.
            What is Altamira Therapeutics Ltd.’s EPS estimate?
            Altamira Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Altamira Therapeutics Ltd. have?
            Altamira Therapeutics Ltd. has 5,715,472 shares outstanding.
              What happened to Altamira Therapeutics Ltd.’s price movement after its last earnings report?
              Altamira Therapeutics Ltd. reported an EPS of -$0.883 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went up 12.5%.
                Which hedge fund is a major shareholder of Altamira Therapeutics Ltd.?
                Currently, no hedge funds are holding shares in CYTOF

                Company Description

                Altamira Therapeutics Ltd.

                Altamira Therapeutics (CYTO) is a biopharmaceutical company focused on developing and commercializing RNA-based therapeutics. The company operates in the biotechnology sector, leveraging its proprietary technology platforms to create innovative treatments for various diseases, including inner ear disorders, nasal and allergy conditions, and other RNA-targeted therapies. Altamira aims to address unmet medical needs by advancing its pipeline of novel products through clinical development and regulatory approval.

                CYTOF Earnings Call

                Q4 2025
                0:00 / 0:00
                Earnings Call Sentiment|Neutral
                Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.Read More>
                Similar Stocks
                Company
                Price & Change
                Follow
                Avadel Pharmaceuticals
                Karyopharm Therapeutics
                TG Therapeutics
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis